168 related articles for article (PubMed ID: 34581019)
1. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
2. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice.
Rodríguez-Nogales C; Mura S; Couvreur P; Blanco-Prieto MJ
Int J Pharm; 2020 May; 582():119345. PubMed ID: 32311470
[TBL] [Abstract][Full Text] [Related]
3. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
4. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Lepeltier E; Bourgaux C; Maksimenko A; Meneau F; Rosilio V; Sliwinski E; Zouhiri F; Desmaële D; Couvreur P
Langmuir; 2014 Jun; 30(22):6348-57. PubMed ID: 24835925
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
7. Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.
Trung Bui D; Maksimenko A; Desmaële D; Harrisson S; Vauthier C; Couvreur P; Nicolas J
Biomacromolecules; 2013 Aug; 14(8):2837-47. PubMed ID: 23829862
[TBL] [Abstract][Full Text] [Related]
8. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
9. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation.
Dosio F; Reddy LH; Ferrero A; Stella B; Cattel L; Couvreur P
Bioconjug Chem; 2010 Jul; 21(7):1349-61. PubMed ID: 20597546
[TBL] [Abstract][Full Text] [Related]
10. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
[TBL] [Abstract][Full Text] [Related]
12. Squalenoyl nanomedicines as potential therapeutics.
Couvreur P; Stella B; Reddy LH; Hillaireau H; Dubernet C; Desmaële D; Lepêtre-Mouelhi S; Rocco F; Dereuddre-Bosquet N; Clayette P; Rosilio V; Marsaud V; Renoir JM; Cattel L
Nano Lett; 2006 Nov; 6(11):2544-8. PubMed ID: 17090088
[TBL] [Abstract][Full Text] [Related]
13. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
14. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
15. Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis.
Wu H; Li B; Shao J; Kong Q
Int J Biol Macromol; 2024 Jun; 269(Pt 2):132019. PubMed ID: 38729498
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
17. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides.
Vale N; Ferreira A; Fernandes I; Alves C; Araújo MJ; Mateus N; Gomes P
Bioorg Med Chem Lett; 2017 Jul; 27(13):2898-2901. PubMed ID: 28495087
[TBL] [Abstract][Full Text] [Related]
19. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Sobot D; Mura S; Rouquette M; Vukosavljevic B; Cayre F; Buchy E; Pieters G; Garcia-Argote S; Windbergs M; Desmaële D; Couvreur P
Mol Ther; 2017 Jul; 25(7):1596-1605. PubMed ID: 28606375
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
